CGRP mAb Subcutaneous denied as non-formulary by Cigna?

Cigna's specific coverage criteria for cgrp mab subcutaneous are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Issued a Non-Formulary Denial for Your CGRP Monoclonal Antibody

A non-formulary denial means the specific CGRP monoclonal antibody your prescriber selected is not included on Cigna's active drug formulary for your plan year, or is placed at a tier that requires an exception before dispensing. Formulary placement is a cost-management decision, not a clinical one — it does not mean the drug is unsafe or ineffective. Cigna plans typically cover at least one CGRP antibody as a preferred formulary agent, so this denial often means the prescriber chose a non-preferred alternative.

## Why This Denial Is Appealable

You have two concurrent paths: (1) a formulary exception requesting that Cigna cover the non-preferred agent at a covered tier, and (2) a standard coverage appeal if the formulary-preferred alternative is clinically inappropriate for you. Federal and state law require plans to grant formulary exceptions when the covered alternative would be contraindicated, clinically ineffective, or likely to cause an adverse reaction for the specific member. If you have already tried the formulary-preferred CGRP antibody and it failed, that history is strong grounds for an exception.

## Your Federal Appeal Rights

• ACA §2719 external review applies if your internal appeal is denied; the window is generally approximately four months after final internal denial.
• ERISA §503 governs self-funded plans and requires a written, reasoned denial with internal appeal rights.
• Many states have separate formulary-exception statutes for fully insured plans that run on shorter timelines — check with your state insurance commissioner if Cigna is your fully-insured carrier.
• Expedited review is available when your condition requires rapid treatment decisions.

## Documentation to Gather

• Formulary-preferred alternative history: if you tried the preferred CGRP agent — dates, prescriber, outcome (non-response, adverse effect, allergy, administration barrier) — with pharmacy records.
• Clinical differentiation rationale: a prescriber letter explaining why the non-preferred agent is specifically required for this patient (mechanism, formulation, dosing schedule affecting adherence, documented failure of alternative).
• Diagnosis and severity records: current chart notes confirming diagnosis and functional impact to establish medical urgency.
• Cigna formulary and exception policy: download the current year's formulary and Cigna's formulary-exception criteria from cigna.com; quote the specific exception criteria your case satisfies.

## Criteria-Mapping Structure

Address the formulary-exception criteria one by one:

| Exception Criterion | Supporting Evidence | |---|---| | Formulary alternative is clinically inappropriate | Prescriber letter + chart note (adverse effect, failure, or contraindication) | | Patient has tried formulary alternative (if required) | Pharmacy dispensing record + visit note with outcome | | Medical necessity of non-preferred agent | Prescriber medical-necessity letter with clinical rationale |

Confirm Cigna's current formulary tier placement and exception requirements by accessing your plan's Summary of Benefits and Coverage and Cigna's published formulary-exception policy before filing.